SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Board appointment

12 Nov 2015 07:00

RNS Number : 4321F
Silence Therapeutics PLC
12 November 2015
 



 

 

 

Board appointment

12th November 2015

 

Silence Therapeutics plc

 

 

Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, is pleased to announced the appointment of Alistair Gray as Non-Executive Director of the Company, with immediate effect. Alistair will also Chair the Audit Committee.

 

Alistair brings with him a wealth of consultancy and business experience. Having trained as an accountant, his early career was in senior management positions with Unilever and John Wood Group PLC. Alistair was a Director of Arthur Young (now Ernst and Young) Management Consultants and PA Consulting Group. Alistair founded Genesis Consulting and, most recently, Renaissance & Company, a strategic management consultancy working with clients across business and sport.

 

Alistair has served as Executive Chairman of the Winning Scotland Foundation and previously served as Chair of British Swimming and British Basketball, leading significant change in both sports. Alistair is currently Chairman of Edrington's Pension Trustees, responsible for management of a major private pension fund and also Chair of the trading division of John Hogg & Company. Alistair chaired the Audit and Remuneration committees of AorTech International PLC and Highland Distillers PLC, as well as the Pension Trustee Board. Alistair also served as a Fellow of the Institute of Directors and Institute of Consultants.

 

 

Stephen Parker Ph.D.  Non-Executive Chairman of Silence Therapeutics, said:

"We are delighted to welcome Alistair to the Board of Silence Therapeutics. His expertise in strategic leadership will be invaluable as we continue to expand our business and seek to deliver value to our shareholders."

 

 

Alistair William Gray, age 67, holds no shares in the Company. He holds or has held the following directorships within the last five years:

 

Current

Renaissance & Company Limited

 

Past

Winning Scotland Foundation (formerly The Scottish Institute of Sport Foundation)

British Swimming Limited

High Performance Swimming Limited

pmpgenesis Limited

Genesis Consulting Limited - dissolved

Genesis Research Limited - dissolved

Genesis Subsidiary Limited - dissolved

Genesis Red Limited - dissolved

 

Genesis Consulting Ltd, a company founded in 1992 by Alistair Gray was put into compulsory liquidation in February 2010. The associated companies were also dissolved.

 

Save as set out above, there are no further disclosures pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

 

 

 

Enquiries:

 

Silence Therapeutics plc

Ali Mortazavi, Chief Executive Officer

Timothy Freeborn, Chief Financial Officer

Tel: +44 (0)20 3457 6900

 

Canaccord Genuity Limited (Nominated Adviser and Joint Broker)

Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel

Tel: +44 (0)20 7523 8350

 

 

Peel Hunt LLP (Joint Broker)

James Steel/Dr Tom Burt/Oliver Jackson

 

Tel: +44 (0)20 7418 8900

Media Enquiries:

FTI Consulting

Simon Conway/Brett Pollard/Stephanie Cuthbert

Tel: +44 (0) 20 3727 1000

 

 

 

 

Notes to Editors

 

About Silence Therapeutics plc

Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.

We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet medical need. In 2015 Silence announced interim results from a Phase 2a pancreatic cancer trial using its compound, Atu027, in combination with gemcitabine.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGMMMMMMKGKZZ
Date   Source Headline
22nd Oct 200712:49 pmPRNHolding(s) in Company
9th Oct 200710:58 amPRNIssue of Equity
2nd Oct 20071:30 pmPRNDirector/PDMR Shareholding
28th Sep 20077:00 amPRNHalf-yearly Report
26th Sep 200711:28 amPRNHolding(s) in Company
10th Sep 20077:00 amPRNResearch Update
6th Sep 20077:05 amPRNNotice of Results
4th Sep 20077:30 amPRNHolding(s) in Company
24th Aug 20074:10 pmPRNHolding(s) in Company
23rd Aug 200712:45 pmPRNHolding(s) in Company
20th Aug 20071:08 pmPRNHolding(s) in Company
16th Aug 200710:12 amPRNHolding(s) in Company
15th Aug 20073:25 pmPRNAIM Rule 26
15th Aug 20072:52 pmPRNHolding(s) in Company
9th Aug 20072:18 pmPRNHolding(s) in Company
9th Aug 20077:01 amRNSHolding(s) in Company
2nd Aug 20073:53 pmPRNHolding(s) in Company
2nd Aug 200710:55 amPRNResult of AGM
31st Jul 200710:27 amPRNTotal Voting Rights
31st Jul 20077:00 amPRNRe Agreement
27th Jul 20077:00 amPRNDirectorate Change
27th Jul 20077:00 amPRNDirectorate Change
20th Jul 200711:35 amPRNHolding(s) in Company
13th Jul 20074:09 pmPRNHolding(s) in Company
11th Jul 20073:37 pmPRNHolding(s) in Company
10th Jul 200712:56 pmPRNHolding(s) in Company
9th Jul 20072:27 pmPRNNotice of AGM
9th Jul 200711:01 amPRNHolding(s) in Company
6th Jul 20074:51 pmPRNIssue of Equity
6th Jul 20071:00 pmPRNRe Agreement
2nd Jul 20074:06 pmPRNIssue of Equity
29th Jun 20077:00 amPRNAnnual Report and Accounts
26th Jun 200711:33 amPRNTotal Voting Rights
21st Jun 20073:28 pmPRNHolding(s) in Company
20th Jun 20071:55 pmPRNCorrection : Holding(s) in Company
15th Jun 20077:00 amRNSConference Attendance
14th Jun 20077:00 amPRNIssue of Equity
13th Jun 20073:20 pmPRNHolding(s) in Company
6th Jun 200711:15 amPRNHolding(s) in Company
30th May 20077:05 amPRNHolding(s) in Company
29th May 20074:20 pmPRNHolding(s) in Company
29th May 200710:44 amPRNHolding(s) in Company
21st May 20073:37 pmPRNIssue of Equity
11th May 20074:26 pmPRNHolding(s) in Company
9th May 200711:45 amPRNIssue of Equity
4th May 20077:01 amRNSSR Pharma Name Change
30th Apr 20071:50 pmPRNTotal Voting Rights
26th Apr 200710:30 amPRNEGM Statement & Research Update
23rd Apr 20077:05 amPRNIssue of Equity
3rd Apr 20079:45 amPRNDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.